影像组学预测乳腺癌受体状态的研究进展
乳腺癌受体状态决定分子分型与诊疗预后,目前依赖有创免疫组化检测且无法动态监测变化。影像组学作为无创方法,有望在无需活检的情况下预测受体状态。本文综述了影像组学预测乳腺癌受体状态的最新研究成果及其潜在临床应用。
要点
- 影像组学可无创预测乳腺癌受体状态,避免反复活检。
- 免疫组化仅反映单时间点受体状态,无法预测治疗或突变后的变化。
- 本文综述影像组学预测乳腺癌受体的最新研究及临床潜力。
核心结论
- 影像组学可能提供一种无需活检即可无创识别乳腺癌受体状态的方法,具有潜在重要临床应用价值。
研究设计与样本
- 本文为综述,汇总影像组学预测乳腺癌受体状态的最新研究成果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Breast cancer is a multifactorial heterogeneous disease and the leading cause of cancer-related deaths in women; its diagnosis and treatment require clinical sensitivity and a comprehensive disciplinary research approach. The expression of different receptors on tumor cells not only provides the basis for molecular typing of breast cancer but also has a decisive role in the diagnosis, treatment, and prognosis of breast cancer. To date, immunohistochemistry (IHC), which uses invasive histological sampling, has been extensively used in clinical practice to analyze the status of receptors and to make an accurate diagnosis of breast cancer. As an invasive assay, IHC can provide important biological information on tumors at a single point in time, but cannot predict future changes (due to treatment or tumor mutations) without additional invasive procedures. These issues highlight the need to develop a non-invasive method for predicting receptor status. The emerging field of radiomics may offer a non-invasive approach to identification of receptor status without requiring biopsy. In this paper, we present a review of the latest research results in radiomics for predicting the status of breast cancer receptors, with potential important clinical applications.
引用
- Lin JY, Ye JY, Chen JG, et al. Prediction of Receptor Status in Radiomics: Recent Advances in Breast Cancer Research. Acad Radiol. 2023. PMID: 38151383. doi:10.1016/j.acra.2023.12.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。